Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | SCN4A | P35499 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832246 | 1.00 | ADRB2 (0.56) | ADRB2TSHRTP53LMNAHTT | |
| SCHEMBL4835179 | 1.00 | ADRB2 (0.56) | ADRB2TSHRTP53LMNAHTT | |
| Hydrochloric Acid SCHEMBL4413207 | 0.97 | ADRB2 (0.54) | ADRB2TSHRTP53LMNAHTT | |
| Hydrochloric Acid SCHEMBL16759200 | 0.97 | ADRB2 (0.54) | ADRB2TSHRTP53LMNAHTT | |
| SCHEMBL27204533 | 0.84 | ADRB2 (0.46) | ADRB2TP53LMNAHTTIDO1 | |
| SCHEMBL1001924 | 0.84 | ADRB2 (0.46) | ADRB2TP53LMNAHTTIDO1 | |
| SCHEMBL16649721 | 0.84 | ADRB2 (0.46) | ADRB2TP53LMNAHTTIDO1 | |
| SCHEMBL12453376 | 0.84 | ADRB2 (0.46) | ADRB2TSHRTP53LMNAHTT | |
| SCHEMBL31001196 | 0.84 | ADRB2 (0.46) | ADRB2TP53LMNAHTTIDO1 | |
| SCHEMBL8204393 | 0.81 | ADRB2 (0.42) | ADRB2TSHRTP53LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | XIZANG HAISCO PHARMACEUTICAL CO LTD (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4534534-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-117510429-A | Compound containing methyl isoxazole structure, and preparation method and application thereof | 中国农业大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-112020357-B | Salt of indazolyl-containing tricyclic derivative and crystal form thereof | 上海翰森生物医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110546150-B | Pyrazolyl-containing tricyclic derivatives, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2021-12-21 | — | — | CN | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| CN-112020357-A | Salts of indazolyl-containing tricyclic derivatives and crystal forms thereof | 上海翰森生物医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| EP-3699179-A1 | PYRAZOLYL-CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| EP-1707564-A2 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-10-04 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| EP-1689737-A1 | BETA-LACTAMS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2005121122-A1 | IMIDAZOL-2-ONE COMPOUNDS USEFUL IN THE TREATMENT OF VARIOUS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005049600-A1 | BETA-LACTAMS FOR TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-6093851-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0735018-B1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL CO (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5739401-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0735018-A1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | ADRB2 1854/4885TSHR 3130/4885TP53 1710/4885 |
| US-20250340532-A1 | HETEROCYCLIC COMPOUND CCR4 INHIBITOR AND USER THEREOF | CCR4, CCR1, CCR3 | ADRB2 2289/4885TSHR 4406/4885TP53 4616/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | ADRB2 892/4885TSHR 3336/4885TP53 1416/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | ADRB2 38/4885TSHR 142/4885TP53 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.